Elan SBI Capital Partners

Elan SBI Capital Partners

Elan SBI Capital Partners was established as a cross-border venture between Elan BioInvest and SBI Holdings, linking US and Asian capital with European and North American life sciences opportunities. The firm is structured as an asset manager rather than a family office, but its roots trace to the capital and networks of its founding partners. The firm's geographic spread—spanning Menlo Park, Cambridge, Baltimore, Basel, and Budapest—reflects a strategy of embedding in key biotech hubs. The firm invests across the life sciences value chain, from early-stage venture through growth equity to buyout-stage opportunities. Asset classes include venture capital, growth equity, and private equity, with a focus on therapeutics, diagnostics, medical devices, and digital health. Notable portfolio positions have included investments in gene therapy platforms, oncology drug developers, and AI-driven diagnostics companies. The firm’s geographic footprint covers North America, Europe, and Asia, with deal sourcing leveraging relationships from its dual-parent heritage. The firm's total assets under management and number of professionals are not publicly disclosed. No philanthropic vehicles or operating companies are publicly associated with the firm. A structural differentiator is the firm's explicit joint-venture model, which blends the scientific and operational expertise of Elan BioInvest with the financial infrastructure of SBI Holdings. This arrangement gives Elan SBI Capital Partners a dual-lens approach—scientific rigor from the Elan side and cross-border capital deployment capability from SBI. The firm operates more like a specialized life sciences asset manager than a traditional family office, with a mandate that covers direct investments and co-investments alongside other institutional partners.